Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
13/07/2026 02:46
BRIEF-Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada July 13 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:
CLINUVEL PHARMACEUTICALS LTD-SCENESSE APPROVED FOR EPP IN CANADA
HEALTH CANADA APPROVES SCENESSE FOR PREVENTION OF PHOTOTOXICITY IN ERYTHROPOIETIC PROTOPORPHYRIA
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist